Johnson & Johnson (JNJ) trades at a trailing P/E of 21.9, forward P/E of 20.8. Trailing earnings yield is 4.56%, forward earnings yield 4.81%. PEG 0.24 (Peter Lynch undervalued ≤1.0). Graham Number is $91.31.
Criteria proven by this page:
Overall SharesGrow Score: 73/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 18.9 | 2.06 | 4.43 | 4.34 | 2.76% |
| 2017 | 288.3 | -3.13 | 6.23 | 4.90 | 2.39% |
| 2018 | 22.5 | 0.02 | 5.75 | 4.21 | 2.76% |
| 2019 | 25.4 | -146.04 | 6.46 | 4.68 | 2.58% |
| 2021 | 28.0 | -10.71 | 6.51 | 4.99 | 2.54% |
| 2022 | 21.6 | 0.52 | 6.09 | 5.73 | 2.45% |
| 2023 | 25.7 | -1.86 | 6.01 | 5.77 | 2.53% |
| 2023 | 11.3 | 0.11 | 5.77 | 4.66 | 2.96% |
| 2024 | 24.5 | -0.42 | 4.83 | 3.88 | 3.43% |
| 2025 | 18.8 | 0.21 | 6.18 | 5.35 | 2.46% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $5.61 | $81.58B | $15.3B | 18.8% |
| 2018 | $5.61 | $81.58B | $15.3B | 18.8% |
| 2019 | $5.63 | $82.06B | $15.12B | 18.4% |
| 2019 | $5.63 | $82.06B | $15.12B | 18.4% |
| 2020 | $5.51 | $82.58B | $14.71B | 17.8% |
| 2021 | $7.81 | $78.74B | $20.88B | 26.5% |
| 2022 | $6.73 | $79.99B | $17.94B | 22.4% |
| 2023 | $13.72 | $85.16B | $35.15B | 41.3% |
| 2024 | $5.79 | $88.82B | $14.07B | 15.8% |
| 2025 | $11.03 | $94.19B | $26.8B | 28.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $11.56 | $11.47 – $11.66 | $100.63B | $98.57B – $101.39B | 13 |
| 2027 | $12.56 | $11.90 – $13.05 | $106.71B | $104.14B – $108.89B | 13 |
| 2028 | $13.73 | $10.81 – $16.03 | $113.17B | $112.96B – $113.38B | 5 |
| 2029 | $15.06 | $14.51 – $15.42 | $119.93B | $116.61B – $122.14B | 2 |
| 2030 | $16.71 | $16.11 – $17.11 | $127.41B | $123.88B – $129.76B | 2 |
